YORK, UK – 20 December 2019 – Biotechnology company Circa Group has announced it is leading the consortium for new EU project ReSolute – a flagship Horizon 2020 project set to develop the first commercial plant to produce Cyrene™ a new, sustainably-sourced, safer alternative to traditional, fossil-based solvents.
Boulder, CO, USA, December 16, 2019 – DMC Biotechnologies has completed additional closings as part of the Company’s Series A funding round which was led by Sofinnova Partners. Boulder Ventures VII L.P. (BV) and SCG have now joined the Series A round bringing the total close to $11.3 million. Current investors Capricorn Partners and Breakthrough Energy Ventures also participated in the round.
Boulder, CO, USA, December 9, 2019 – An essential patent has been allowed for DMC Biotechnologies’ Dynamic Metabolic Control technology.
Patent number PCT/US2015/035306 with the title ‘Compositions and methods for rapid and dynamic flux control using synthetic metabolic valves’ has been issued by the United Kingdom Intellectual Property Office (UKIPO) to Duke University. DMC has the exclusive license to the technology from Duke.
“The last ten years have shown that bringing biobased products to market takes time. Our Dynamic Metabolic Control technology can accelerate commercialization by making fermentation scale-up more predictable, robust, and efficient. Receiving this patent allowance is another milestone for DMC and is meaningful to our team, our partners, and our investors,” said Matt Lipscomb, Ph.D., CEO & Co-Founder of DMC.
Pearl River, NY, USA, 6 December 2019 – Sustainable technology company Anellotech is significantly expanding its program with Plas-TCatTM, a new process technology aiming to convert a wide range of plastic waste directly into chemicals – which can then be used to make new, virgin plastics.
[Boulder, CO] November 18, 2019 – The US National Science Foundation (NSF) has awarded an additional $500,000 to DMC through its Small Business Innovation Research (SBIR) Phase IIB program. This is in addition to over $960,000 previously awarded to DMC by NSF through the SBIR Phase I and II programs. The additional funding will support the ongoing commercialization efforts of DMC’s Dynamic Metabolic Control technology platform and will help accelerate the company’s commercialization efforts.
